DDInter71 DDInter1658
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Aminoglutethimide {u} (Compound) resembles {v} (Compound) Glutethimide
Aminoglutethimide {u} (Compound) binds {v} (Gene) CYP19A1
Aminoglutethimide {u} (Compound) is included by {v} (Pharmacologic Class) Adrenal Steroid Synthesis Inhibitors
Aminoglutethimide {u} (Compound) downregulates {v} (Gene) PSMB8
Aminoglutethimide {u} (Compound) causes {v} (Side Effect) Anaemia
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Aminoglutethimide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acalabrutinib
Aminoglutethimide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Aminoglutethimide {u} may lead to a major life threatening interaction when taken with {v} Lumateperone
Aminoglutethimide (Compound) resembles Glutethimide (Compound)
Aminoglutethimide (Compound) binds CYP19A1 (Gene)
Aminoglutethimide (Compound) is included by Adrenal Steroid Synthesis Inhibitors (Pharmacologic Class)
Aminoglutethimide (Compound) downregulates PSMB8 (Gene)
Aminoglutethimide (Compound) causes Anaemia (Side Effect)
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Glimepiride
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib
Aminoglutethimide may lead to a major life threatening interaction when taken with Lumateperone